The
California PH Conference - held June 25-26, 2005
- was attended by over 200 people, including patients,
friends & family, medical professionals, and representatives
from leading PH drug companies.
The
event earned high marks for the informative talks,
good food, and friendly atmosphere.
This
was our biggest turnout since the forum began in
1999 and we see the event growing and growing. We
look forward to hosting another in 2007.
Over
half of US House of Representatives co-sponsors PH Research
Act
Of
the 435 US Representatives, 221 are currently signed
on as sponsors of the PH Research Act, and new sponsors
are being added daily. Learn more about the Act, make
sure your Representative is a sponsor, and Take Action!
at www.phassociation.org/advocacy/phra.asp
Myogen
Announces Completion of Enrollment for Pivotal Phase 3 ARIES-2
Trial of Ambrisentan in PAH
DENVER, July 21 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG -
News), a biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced the completion of enrollment of
187 patients in ARIES-2, one of the Company's two pivotal Phase 3 trials of
ambrisentan in patients with pulmonary arterial hypertension (PAH). The
Company expects to report top line results of the trial by the end of this
year. In addition, the Company expects to complete patient enrollment in
ARIES-1 in the fourth quarter of 2005 and report top line results
approximately six months thereafter.
Lung
transplant: A treatment for life-threatening lung disease
Your lungs transfer
the oxygen you inhale to your blood, and they remove from
your blood carbon dioxide, which you exhale. Damage to various
structures in your lungs can affect how well you breathe
or how efficiently the organs exchange oxygen and carbon
dioxide.
Some medications or breathing-assistance devices may help
improve the function of your lungs. When these therapies
are no longer beneficial or poor lung function is life-threatening,
your doctor may recommend a lung transplant.
Before making a decision about a lung transplant, know what
to expect of the organ transplant process, the surgery itself,
potential risks and follow-up care.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Express Scripts acquisition improves specialty drug position
Express Scripts
Inc. of Maryland Heights will become one of the nation's
largest distributors of specialty-drug prescriptions with
its planned $1.3 billion cash purchase of Priority Healthcare
Corp. of Lake Mary, Fla. The deal was announced Thursday
night.
For
Medical Professionals:
With the advent of new PH drugs and treatments, more
and more doctors are becoming increasingly involved
in the PH community. PHA has responded to this, and
will bring together world-renowned leading PH specialists
to lead Medical Education Sessions for their peers
during the fall in six cities: New York; Atlanta;
Chicago; Seattle; Dallas; and Washington, DC
Physicians
who participate
are eligible to receive CME credits. Educational credits
will also be available for nurses and pharmacists.
For questions
or to register by phone, please call 858-717-2940.
For Patients:
While we are bringing together leading specialists
and interested medical professionals for the Medical
Education Sessions, we know that patients will also
greatly benefit from these gatherings. We are therefore
very excited to announce PHA's Regional Patient Education
Sessions.
Many of the medical professionals presenting earlier
during the day will stay for the evening's PHA Regional
Patient Education Session to participate in a dinner,
educational slide-show and panel discussion of current
advances in PH. Kim Bernstein, director of ACCESS,
will also be at each session, presenting on insurance
issues and how to use her program as an important
resource.
Partnering with Actelion and Accredo
Therapeutics we are able to allow a free ticket to
each patient and one guest (a 50 dollar value), up
to the first 200 registrants. This includes dinner
and the presentations. Any additional guests or registrations
after the first 200, will need to purchase a ticket
at $25. PH patients with Scleroderma are also invited
to attend a Scleroderma Support Group meeting taking
place earlier in the day.
PHA thanks Actelion, our primary sponsor,
and Accredo Therapeutics for their generous support
of this program.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
Of
the 435 US Representatives, 221 are currently signed
on as sponsors of the PH Research Act, and new sponsors
are being added daily. Learn more about the Act, make
sure your Representative is a sponsor, and Take Action!
at 
